Prognosis
Fourth Dose of mRNA Vaccine Adds Covid Protection in U.K. Trial
This article is for subscribers only.
Fourth doses of messenger RNA vaccines added to the protection received from a third shot in a U.K. trial that underscores the benefits of boosters for the most vulnerable people.
The research, published Monday in The Lancet Infectious Diseases journal, found that fourth doses of mRNA vaccines can provide a significant increase in antibody levels in people who received Pfizer Inc.’s vaccine as a third dose. They’re also effective at raising protection potentially above peak levels seen after third doses, according to the latest findings from the trial.